Registered Tanzania · TMDA

BSV-HUMOG 75 HP

Menotrophin 75 IU

TZ 18 H 0074 Injection

What it does

Menotrophin is a medication used to help treat fertility issues by stimulating the ovaries to produce eggs.

Commonly used for: infertility, ovarian stimulation

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.

Sourcing - Kenya only

Registration & product details

Registration no.
TZ 18 H 0074
Registration date
2023-03-02
Expiry date
2028-03-01
Status
Registered/Compliant
Active ingredient
Menotrophin 75 IU
Dosage form
Injection
Strength
-
Pack size
-
Therapeutic class
-
Manufacturer / MAH
Bharat Serums And Vaccines
Country of origin
INDIA
Manufacturer location
3RD Floor, Liberty Tower, Plot No. K-10, behind Reliable Plaza, Kalwa Industrial Estate, Gavate Wadi, MIDC, Airoli, Navi Mumbai, Maharashtra 400708, India

Source: Tanzania Medicines and Medical Devices Authority · fetched 2026-03-11 23:43:56 · updated 2026-09-17 03:00:44

Disclaimer: This information is sourced from Tanzania Medicines and Medical Devices Authority (Tanzania). Always consult a qualified healthcare professional before using any medication.

About this medicine

Menotrophin is a medication used to help treat fertility issues by stimulating the ovaries to produce eggs.

What it treats

  • infertility
  • ovarian stimulation

How it works

Menotrophin contains hormones that encourage the ovaries to produce eggs, which is important for women trying to conceive.

Who it's for

This medication is for women who have difficulty getting pregnant due to issues with egg production.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: Menotrophin

BNF-referenced

Menotrophin is a gonadotropin preparation containing both follicle-stimulating hormone (FSH) and luteinizing hormone (LH). It is used in fertility treatments to stimulate the ovaries in women with certain types of infertility, particularly those with hypopituitarism or who have not responded to clomifene.

Indications

  • Gonadotropin replacement therapy
  • Treatment of infertility in women with proven hypopituitarism
  • Superovulation for assisted conception, such as in vitro fertilization

Dosage

Adults: Initial dosing should be based on serum anti-Müllerian hormone concentration and body weight. Adjust doses according to response, under specialist supervision.

Mechanism of action

Menotrophin works by mimicking the natural hormones FSH and LH, which stimulate the ovaries to produce mature follicles. FSH promotes the growth and maturation of ovarian follicles, while LH triggers ovulation. This coordinated action is essential for the development of eggs and the regulation of the menstrual cycle.

Pharmacodynamics

Menotrophin enhances ovarian response in women undergoing assisted reproductive techniques by facilitating follicular development and maturation. It is crucial in protocols for in vitro fertilization (IVF) as it increases the number of viable oocytes available for retrieval.

Pharmacokinetics

After subcutaneous administration, menotrophin is absorbed into the bloodstream, with peak serum concentrations occurring after a variable time depending on the individual. The elimination half-life is not well-defined, but the hormone activity is generally maintained to support ovarian stimulation over several days. The pharmacokinetics can be influenced by the individual's hormonal status and response to treatment.

Contra-indications

  • Mammary carcinoma
  • Uterine carcinoma
  • Ovarian hyperstimulation syndrome
  • Pelvic disorders

Adverse effects

  • Fatigue
  • Headache
  • Nausea
  • Gastrointestinal discomfort
  • Pelvic pain
  • Vomiting
  • Thromboembolism
  • Ovarian and fallopian tube disorders

Precautions

  • Regular monitoring of ovarian response with ultrasound or in combination with serum estradiol levels is required.
  • Patients should be advised to withhold hCG and avoid intercourse or use barrier contraceptive methods for at least 4 days if ovarian hyperstimulation syndrome occurs.

Pregnancy

Manufacturer advises to avoid-not indicated during pregnancy.

Breast-feeding

Manufacturer advises to avoid-not indicated during breastfeeding.

Storage

Store in a refrigerator (2°C to 8°C). Do not freeze.

Formulations

  • Powder and solvent for solution for injection vials
  • Pre-filled disposable injection pens
BNF 85 (British National Formulary) p.835 PubChem / pathway

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

This drug in other countries

The same active ingredient registered across other registries we cover - including different brands.